ST VINCENT'S HOSPITAL MELBOURNE

St Vincent's PET/CT Centre
Basement Level, 41 Victoria Pde, Fitzroy VIC 3065
PET.Melb@svha.org.au
Tel: 9231 3071 Fax: 9231 3090

Compassion | Justice | Integrity | Excellence

Patient Details: *affix patient label here*	*Handwritten Confirmation of Patient Details*
Surname: UR:	Name:
First Name:	UR Number:
DOB:	Interpreter Required:
Address:	Language:
Phone:	Is the Patient Diabetic:

Patient Referred From (please specify) Outpatient Clinic/Inpatient Ward:

Requesting Doctor (*please note: Patients MUST be referred by a Specialist to obtain a Medicare Rebate for PET imaging*)

Name: Phone: Fax:

Address: Provider Number:

Signature: Date

Relevant Clinical History

Group 1: Staging/Diagnosis (eligible for Medicare rebate). **Please select the appropriate indication**

Whole Body ^{18}F-FDG Study for:

- ☐ Solitary pulmonary nodule (not suitable for FNAB), or if attempt at pathological characterisation has failed
- ☐ Staging of NSCLC (Lung Carcinoma) being considered for curative surgery or radiotherapy
- ☐ Staging of newly diagnosed previously untreated Hodgkin's or non-Hodgkin's lymphoma
- ☐ Staging of biopsy proven newly diagnosed head and neck carcinoma
- ☐ Evaluation of metastatic squamous cell carcinoma from unknown primary involving cervical nodes
- ☐ Staging of newly diagnosed oesophageal carcinoma or GEJ in patients considered suitable for active therapy
- ☐ Further primary staging of histologically proven carcinoma of the uterine cervix (FIGO stage IB2 or greater) prior to planned radical radiotherapy or combined modality therapy with curative intent
- ☐ Initial staging of patients with biopsy proven bone or soft-tissue sarcoma (excluding GIST) considered by conventional staging to be potentially curable
- ☐ Staging of locally advanced (Stage III) Breast cancer

^{68}Ga-DOTATATE study for:

- ☐ Staging of biochemically suspected GEP Neuroendocrine tumours or assessment of resectability of metastatic GEP neuroendocrine tumours

^{18}F-DCFPyL (PSR) Prostate PSMA PET study for:

- ☐ Initial staging of intermediate to high-risk Prostate Ca, for a previously untreated patient considered suitable for therapy with curative intent (*Once per lifetime)

PLEASE ENSURE BOTH PAGES OF THE REFERRAL ARE COMPLETED

Patient Surname: **First Name:** **DOB:**

Group 2: Restaging/Recurrence (eligible for a Medicare rebate) **Please select the appropriate indication**

Whole Body ^{18}F-FDG Study for:

- ☐ Assess response to first line therapy for Hodgkin's or non-Hodgkin's lymphoma (either during treatment or within 3 months of completing definitive first line treatment
- ☐ Restaging of confirmed recurrence of Hodgkin's or non-Hodgkin's lymphoma
- ☐ Assess response to second line chemotherapy (where stem cell transplantation is being considered) for Hodgkin's or non-Hodgkin's lymphoma
- ☐ Suspected residual or recurrent head and neck carcinoma (after definitive treatment in patients considered suitable for active therapy)
- ☐ Following initial therapy for suspected residual, metastatic or recurrent colorectal carcinoma in patients suitable for active therapy
- ☐ Following initial therapy for suspected metastatic or recurrent malignant melanoma in patients suitable for active therapy
- ☐ Further staging, confirmed recurrence of uterine cervix carcinoma suitable for salvage pelvic chemoradiotherapy or exenteration
- ☐ Suspected residual or recurrent sarcoma (excluding GIST) after initial therapy to assess suitability for subsequent curative treatment
- ☐ Following initial therapy for suspected residual, metastatic or recurrent ovarian carcinoma in patients suitable for active treatment
- ☐ Suspected metastatic, or suspected recurrent Breast cancer

^{18}F-FDG Study of Brain for:

- ☐ Evaluation of refractory epilepsy being evaluated for surgery
- ☐ Diagnosis of Alzheimer's Disease (*3 per lifetime)
- ☐ Suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy or during ongoing chemotherapy, in patients who are considered suitable for active therapy

^{18}F-DCFPyL (PSR) Prostate PSMA PET study for:

- ☐ Restaging of recurrent Prostate cancer for a patient who has undergone prior therapy and to determine next treatment options. (*2 per lifetime)

Group 3: Additional Indications (the following indications are NOT currently eligible for a Medicare rebate*)

- ☐ Prostate Cancer ^{18}F-DCFPyL *Non-rebatable indication*
- ☐ Small cell lung carcinoma (note: non-small cell lung funded)
- ☐ Cardiac FDG PET (cardiac sarcoid)
- ☐ Gastric carcinoma (note gastro-esophageal junction funded)
- ☐ Liver or biliary cancer
- ☐ Neuroendocrine carcinoma ^{18}F-FDG PET (note ^{68}Ga-DOTA PET funded)
- ☐ Endometrial carcinoma
- ☐ Myeloma
- ☐ Genitourinary cancers
- ☐ Bone cancers
- ☐ Metastases from unknown primary
- ☐ Infection / Inflammation
- ☐ Other:

*Referrers are asked to ensure patients are aware that there will be a charge for PET scans that do not attract a Medicare rebate.

Clinical Trials

Is the patient on a clinical trial: ☐ Yes

Trial Name/Code:

Trial coordinator:

Coordinator signature:

*Please note: the CT performed as part of a PET/CT is not diagnostic. If you require a separate diagnostic CT please complete the below:

☐ **Diagnostic CT required,**
CT Region / Clinical History:

Renal Function:

Normal ☐

Abnormal ☐

eGFR:

Date:

Details of Radiopharmaceutical:

Radiopharmaceutical Label:

SVPR023 10/22

Tel: 9231 3071 E-mail: PET.Melb@svha.org.au Fax: 9231 3090